The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- 17 August 2010
- journal article
- Published by Elsevier BV in Cancer Cell
- Vol. 18 (2), 160-170
- https://doi.org/10.1016/j.ccr.2010.06.014
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- A novel interaction between HER2/neu and cyclin E in breast cancerOncogene, 2010
- CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune ResponsesScience, 2009
- Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLEThe Journal of Experimental Medicine, 2008
- Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune responseProceedings of the National Academy of Sciences of the United States of America, 2008
- DNA Vaccination Controls Her-2+ Tumors that Are Refractory to Targeted TherapiesCancer Research, 2008
- Adaptive immune cells temper initial innate responsesNature Medicine, 2007
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Targeting the function of the HER2 oncogene in human cancer therapeuticsOncogene, 2007
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987